Bernstein analyst Eve Burstein lowered the firm’s price target on Illumina (ILMN) to $140 from $145 and keeps a Market Perform rating on the ...

Illumina has begun rolling out a series of updates to its top-of-the-line DNA sequencer models, with the goal of making the ...

Illumina, Inc. ILMN has announced a series of updates to its NovaSeq X Series. The company’s single-flow-cell NovaSeq X Sequencing System is now available for the first time, alongside the software v1 ...

ClariMed, Inc., a global leader in human-centered medical device development and regulatory services, has announced the ...

MAIA Biotechnology, Inc., ("MAIA", the "Company"), a clinical-stage biopharmaceutical company developing targeted immunotherapies for cancer, today announced that it has entered into a clinical supply ...

Illumina (ILMN) announced a series of updates to its NovaSeq X Series, delivering the NovaSeq X single-flow-cell system alongside a software ...

Illumina, Inc. (NASDAQ: ILMN), a global leader in DNA sequencing and array-based technologies, today announced a series of ...

While Illumina completed the takeover of Grail last September, it has maintained the business as a separate subsidiary company while it waits for the outcome of antitrust reviews in the US and Europe.

The Federal Trade Commission has ordered Illumina to divest Grail, the cancer detection business it bought for $7.1 billion in 2021, saying it will “stifle” competition and innovation in the US.